PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo StudyFu-Shun Hsu, Kuo‐How Huang, Wei‐Chou Lin et al.|International Journal of Molecular Sciences|2021Cited by 27
Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK PathwayFu-Shun Hsu, Kuo‐How Huang, June‐Tai Wu et al.|International Journal of Molecular Sciences|2019Cited by 25
Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo StudyKuan-Lin Kuo, Kuo‐How Huang, Fu-Shun Hsu et al.|International Journal of Molecular Sciences|2019Cited by 25
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo StudyChung‐Sheng Shi, Kuo‐How Huang, Kuan-Lin Kuo et al.|Cells|2019Cited by 16
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinomaWei‐Chou Lin, Kuo‐How Huang, Fu-Shun Hsu et al.|Journal of Molecular Medicine|2018Cited by 9